The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial
Open accessAbstract
BACKGROUND: The role of axillary lymph node dissection (ALND) has increasingly been called into question among patients with positive sentinel lymph nodes. Two recent trials have failed to show a survival difference in sentinel node-positive breast cancer patients who were randomized either to undergo completion ALND or not. Neither of the trials, however, included breast cancer patients undergoing mastectomy or those with tumors larger than 5 cm, and power was debatable to show a small survival difference. METHODS: The prospective randomized SENOMAC trial includes clinically node-negative breast cancer patients with up to two macrometastases in their sentinel lymph node biopsy. Patients with T1-T3 tumors are eligible as well as patients prior to systemic neoadjuvant therapy. Both breast-conserving surgery and mastectomy, with or without breast reconstruction, are eligible interventions. Patients are randomized 1:1 to either undergo completion ALND or not by a web-based randomization tool. This trial is designed as a non-inferiority study with breast cancer-specific survival at 5 years as the primary endpoint. Target accrual is 3500 patients to achieve 80% power in being able to detect a potential 2.5% deterioration of the breast cancer-specific 5-year survival rate. Follow-up is by annual clinical examination and mammography during 5 years, and additional controls after 10 and 15 years. Secondary endpoints such as arm morbidity and health-related quality of life are measured by questionnaires at 1, 3 and 5 years. DISCUSSION: Several large subgroups of breast cancer patients, such as patients undergoing mastectomy or those with larger tumors, have not been included in key trials; however, the use of ALND is being questioned even in these groups without the support of high-quality evidence. Therefore, the SENOMAC Trial will investigate the need of completion ALND in case of limited spread to the sentinel lymph nodes not only in patients undergoing any breast surgery, but also in neoadjuvantly treated patients and patients with larger tumors. TRIAL REGISTRATION: NCT 02240472 , retrospective registration date September 14, 2015 after trial initiation on January 31, 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795 · cited 1×
“ments used are the Lymphedema Functioning, Disability and Health Questionnaire (Lymph-ICF) [25], the EQ5D-5 L utility scores [26], and EORTC’s well-validated QLQ-30 [27, 28] and BR-23 [29] questionnaires.”
MethodSprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220
Cited by
Axillary Nodal Evaluation in Breast Cancer: State of the Art
Chang, J. M., Leung, J. W. T., Moy, L., Ha, S. M., & Moon, W. K. (2020) · Radiology · doi:10.1148/radiol.2020192534 · Cited by 387
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
de Boniface, J., Filtenborg Tvedskov, T., Rydén, L., Szulkin, R., Reimer, T., Kühn, T., Kontos, M., Gentilini, O. D., Olofsson Bagge, R., Sund, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313487 · Cited by 307
Self-citationBrackstone, M., Baldassarre, F. G., Perera, F. E., Cil, T., Chavez Mac Gregor, M., Dayes, I. S., Engel, J., Horton, J. K., King, T. A., Kornecki, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00934 · Cited by 271
Metadata
- Authors
- on behalf of the SENOMAC Trialists’ Group, de Boniface, J., Frisell, J., Andersson, Y., Bergkvist, L., Ahlgren, J., Rydén, L., Olofsson Bagge, R., Sund, M., Johansson, H., & Lundstedt, D.
- Venue
- BMC Cancer
- Published
- 2017-05-26
- Volume
- 17
- Issue
- 1
- Pages
- 379-379
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2619961270
- Cited by
- 174
- References
- 3
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. https://app.cochat.ai/papers/10.1186/s12885-017-3361-y
- The paper
- on behalf of the SENOMAC Trialists’ Group, de Boniface, J., Frisell, J., Andersson, Y., Bergkvist, L., Ahlgren, J., Rydén, L., Olofsson Bagge, R., Sund, M., Johansson, H., & Lundstedt, D. (2017). Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. https://doi.org/10.1186/s12885-017-3361-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.